The size of the atopic dermatitis market in North America is expected to grow from USD 3.79 billion in 2023 to USD 7.12 billion by 2028, growing at a CAGR of 13.4% from 2023 to 2028.
The growing prevalence of atopic dermatitis disease across all age groups across North America primarily drives the growth of the atopic dermatitis market in the North American region. Approximately 16.5 million adults in the United States alone are affected. Atopic dermatitis, known as eczema, is a chronic condition characterized by inflammation, skin irritation and redness. While the disease often begins in childhood, it is not contagious and does not spread between individuals. Factors such as genetic changes, compromised immune systems and adverse environmental conditions contribute to the development of atopic dermatitis. Common symptoms include dry, cracked skin, rash and the presence of raised bumps.
The continuous development of diverse drug options to address atopic dermatitis further propels the North American atopic dermatitis market growth. The ongoing research and development, support from public and private organizations and increased approvals for novel medications drive the regional market growth. Rising demand for effective treatment options to manage the symptoms of atopic dermatitis, advancements in drug development and therapies specifically designed for atopic dermatitis and growing awareness among healthcare providers and patients about the condition and available treatment options further boost the growth rate of the North American market.
Supportive government initiatives and funding for research and development in the field of dermatology, expansion of pharmaceutical companies' product portfolios to include atopic dermatitis treatments, growing investments in research and clinical trials for the development of novel therapies and rising emphasis on personalized and targeted therapies for atopic dermatitis patients promotes the atopic dermatitis market growth in the North American region. Improved understanding of the underlying causes and mechanisms of atopic dermatitis and technological advancements in diagnostic tools and treatment delivery methods for enhanced patient care support the regional market growth.
The high cost of treatment and medications for atopic dermatitis hampers the North American market growth. Factors such as the lack of skilled professionals, low awareness, stringent regulations and high production costs for medications further hinder the North American market growth. The potential side effects of skin ointments and medications hinder the regional market growth.
This research report on the North American atopic dermatitis market has been segmented and sub-segmented into the following categories.
North America Atopic Dermatitis Market - By Treatment Type:
North America Atopic Dermatitis Market - By Route of Administration:
North America Atopic Dermatitis Market - By Distribution Channel:
North America Atopic Dermatitis Market - By Country:
North America is predicted to account for the largest share of the global market during the forecast period owing to factors such as the presence of advanced medical facilities, increased healthcare expenditure and awareness programs by healthcare organizations. The U.S. is estimated to hold the major share of the North American market in the coming years. The strong presence of pharmaceutical companies, reimbursement policies, mergers and acquisitions and government programs drive the U.S. market growth. Canada is anticipated to hold a considerable share of the North American market during the forecast period. The government initiatives, the availability of atopic dermatitis drugs and the prevalence of other skin disorders in the population propel the growth of the Canadian market growth.
KEY MARKET PLAYERS:
A few of the companies that are playing a notable role in the North American atopic dermatitis market profiled in the report are Astellas Pharma Inc., Valeant Pharmaceuticals International, Inc., and Sanofi S.A. Other players in the market include Anacor Pharmaceuticals, Inc. Meda Pharmaceuticals, Regeneron Pharmaceuticals Inc., Novartis International AG, and Pfizer, Inc.
The United States holds the largest market share in North America for atopic dermatitis market, followed by Canada.
Factors such as increasing prevalence, rising awareness, and advancements in treatment options are driving the growth of the atopic dermatitis market in the United States.
Challenges include the high cost of treatments, regulatory hurdles, and the need for more effective long-term management strategies.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com